Clinical Variant of Guillain-Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine.

Journal article

Peer reviewed

Anca Badoiu, Olivier Moranne, Sarah Coudray and Ioana Maria Ion

Journal of Clinical Neuromuscular Disease, Vol.23(2), pp.115-116

01/12/2021

PMID: 34808658

Abstract

COVID-19

COVID-19 Vaccines

ChAdOx1 nCoV-19

Facial Paralysis

Female

Guillain-Barre Syndrome

Humans

Middle Aged

SARS-CoV-2

url

Find in HALView

1 Record Views

Title: Clinical Variant of Guillain-Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine.
Creators - without role: Anca Badoiu - Centre Hospitalier Universitaire de Nîmes
Olivier Moranne - Centre Hospitalier Universitaire de Nîmes
Sarah Coudray - Centre Hospitalier Universitaire de Nîmes
Ioana Maria Ion - Centre Hospitalier Universitaire de Nîmes
Publication Details: Journal of Clinical Neuromuscular Disease, Vol.23(2), pp.115-116
Identifiers: 9939446909311
Academic Unit: Institut Desbrest d Epidemiologie et de Sante Publique - IDESP
Language: English
Resource Type: Journal article
Local Fields: hal-03621358